Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 3/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10449139 | 0.83 | PKM (0.57) | ALDH1A1LMNASMN1; SMN2HTTPKM | |
| SCHEMBL5622356 | 0.82 | PGR (0.79) | ALDH1A1LMNAPKMKEAP1PGR | |
| SCHEMBL20960702 | 0.79 | TUBB4A (0.52) | ALDH1A1LMNASMN1; SMN2HTTPKM | |
| SCHEMBL7770162 | 0.79 | KEAP1 (0.60) | HTTPKMKEAP1PGRNFE2L2 | |
| SCHEMBL23536525 | 0.78 | ALDH1A1 (0.66) | ALDH1A1LMNASMN1; SMN2HTTKEAP1 | |
| SCHEMBL10950108 | 0.78 | LMNA (0.85) | ALDH1A1LMNASMN1; SMN2HTTPGR | |
| SCHEMBL20733374 | 0.78 | LMNA (0.66) | ALDH1A1LMNASMN1; SMN2HTTPKM | |
| SCHEMBL5612071 | 0.78 | LMNA (0.85) | ALDH1A1LMNASMN1; SMN2HTTPGR | |
| SCHEMBL4204765 | 0.78 | LMNA (0.76) | ALDH1A1LMNASMN1; SMN2HTTPKM | |
| SCHEMBL10872609 | 0.78 | PKM (0.55) | ALDH1A1LMNASMN1; SMN2HTTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0694041-A1 | A PROCESS AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS CONTAINING N-ALPHA-METHYLARGININE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-31 | — | — | EP | claimed |
| CN-117535689-A | Method for synthesizing sulfonamide through decarbonylation of N, N-dimethylformamide and denitrification of sulfonyl hydrazide under electrochemical condition | 湘潭大学 | 2024-02-09 | — | — | CN | disclosed |
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023196342-A1 | α4β1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023096904-A2 | C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-4164752-A1 | INHIBITORS OF TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4161651-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4081202-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-4027993-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| US-5681840-A | ANTIDOPAMINERGIC AGENTS | ZENECA LIMITED (GB) | 1997-10-28 | — | — | US | disclosed |
| EP-0532177-B1 | Methanoanthracenes as dopamine antagonists | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | disclosed |
| EP-0533344-B1 | Methanoanthracenes as dopamine antagonists | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | disclosed |
| US-5550136-A | ANTAGONISTS OF DOPAMINE D-2 RECEPTORS | ZENECA LIMITED (GB) | 1996-08-27 | — | — | US | disclosed |
| US-5512575-A | ANTISEROTONINE AGENT | ZENECA LIMITED (GB) | 1996-04-30 | — | — | US | disclosed |
| EP-0389861-B1 | Benzopyran derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-08-23 | — | — | EP | disclosed |
| US-5399568-A | Dopamine antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-03-21 | — | — | US | disclosed |
| EP-0532177-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | disclosed |
| US-5104890-A | Potassium channel activtors; vasodilators | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0389861-A1 | Benzopyran derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-03 | — | — | EP | disclosed |